Immunovant (NASDAQ:IMVT) Given Buy Rating at HC Wainwright

robot
Abstract generation in progress

HC Wainwright reaffirmed its “buy” rating on Immunovant (NASDAQ:IMVT) with a $35.00 price objective, suggesting a potential upside of 27.32%. Other analysts have also adjusted their ratings and price targets for the biopharmaceutical company, resulting in a consensus “Moderate Buy” rating and a price target of $31.11. Insider selling and institutional investor activity have also been noted, with the stock currently trading at $27.49.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)